The global CNS biomarkers sales market is expected to grow to $3.4 billion by 2015 and account for 15% of the entire Biomarker Market. The CNS Biomarkers Congress 2013, co-located with the 8th Annual Biomarkers Congress will provide the opportunity for two days worth of in depth analysis and insight into the CNS Biomarkers market. Hear over twenty CNS specific presentations, roundtable and panel discussion sessions that will explores key issues such as:- CNS biomarker case studies in AD, Parkinsons, Epiliepsy, MS Supporting CNS Drug Development using biomarkers Challenges in CNS Biomarkers CSF biomarkers Industry / Academic collaborations Anti amyloid therapies for Alzheimer’s disease NeuroImaging Technology case studies for CNS